Table.

Study Population Baseline Characteristics and Demographics

	Intravitreal Fluocinolone Acetonide, n = 130 Patients, 160 Eyes
Patient age, mean y	69.6
Male, %	53.8
Race, %
White	89.2
Black/African American	6.2
Asian	0.8
Other	3.8
Diabetes type, %
Type 1	10.0
Type 2	87.7
Not Recorded	2.3
HbA1C, mean %	7.07
Time since diagnosis, mean y (range)
Diabetes	24.1 (2–56)
DME	4.4 (0–32)
Lens status, %
Phakic	22.5
Pseudophakic	68.8
Not recorded	8.7
Prior treatment, no. of eyes (%)	146 (91.3)
Anti-VEGF	123 (76.9)
Steroid	90 (56.3)
Laser	80 (50.0)
Duration of follow-up, mean d (range)
Pre-FAc	903.3 (35–4005)
Post-FAc	407.8 (7–756)